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ABSTRACT
Platelets and other blood components are often transfused in clinical settings associated with hypothermia and a bleeding diathesis, such as cardiopulmonary bypass surgery, other major surgery, and multiple trauma. We examined the hypothesis that hypothermia reversibly inhibits human platelet activation in vitro and in vivo. Methods: Platelet activation was studied in normal human volunteers by whole blood flow cytometric analysis of modulation of platelet surface GMP-140 and the glycoprotein (GP) Ib-IX complex in a) shed blood emerging from a standardized in vivo bleeding time wound and b) peripheral blood activated in vitro with either a-thrombin (in the presence of gly-pro-arg-pro, an inhibitor of fibrin polymerization) or the stable thromboxane A 2 analogue U46619. Platelets in peripheral whole blood were activated at temperatures between 22°C and 37°C. The skin temperature of the forearm was maintained at temperatures between 22°C and 37°C prior to and during the bleeding time incision. Platelet aggregation was studied in shed blood by flow cytometry using a gate on both GPIb-positivity and light scatter and in peripheral blood by aggregometry. Results: In vitro, hypothermia inhibited the rate and extent of both thrombin-and U46619-induced a) upregulation of GMP-140, b) downregulation of the GPIb-IX complex, c) platelet aggregation, d) platelet shape change, and e) thromboxane B2 generation. These inhibitory effects of hypothermia were all completely reversed by rewarming the blood to 37°C. In vivo, platelet activation was inhibited by hypothermia as shown by 5 independent assays of shed blood: 1) upregulation of GMP-140, 2) downregulation of the GPIb-IX complex, 3) platelet aggregate formation, 4) thromboxane B2 generation, and 5) the bleeding time. Summary: By a combination of immunological, biochemi-
INTRODUCTION
Hypothermia occurs frequently in a number of clinical settings, including hypothermic cardiopulmonary bypass surgery, other major surgery, multiple trauma, exposure, and neonatal cold injury. A hypothermia-induced hemorrhagic diathesis is associated with these clinical settings (1-7). However, the pathophysiological basis of this hemorrhagic diathesis is not well understood. Hypothermia has been reported to induce a platelet function defect in baboons, as evidenced by diminished generation of thromboxane Bj (8) and prolongation of the bleeding time (2, 8) . Hypothermia also results in prolongation of the bleeding time in humans (9) . However, the specificity of the relationship between the bleeding time and platelet function has been challenged (10) .
In the present study, we tested the hypothesis that hypothermia inhibits human platelet activation in whole blood in vitro and in vivo. We utilized the following combination of immunological, biochemical, and functional assays of platelet activation: upregulation of the platelet surface expression of GMP-140 (reflecting a granule secretion) (11) , downregulation of the platelet surface expression of the GPIb-IX complex (the von Willebrand factor receptor) (12) , thromboxane Bj generation (the stable metabolite of thromboxane A2) (13), platelet aggregate formation (14) , and the bleeding time. Because platelets and other blood components are often transfused in clinical settings associated with hypothermia, we also examined the possibility that the safer and less expensive measure of rewarming could reverse the putative hypothermia-induced platelet activation defect.
METHODS
Murine Monoclonal Antibodies
S12 (provided by Dr. Rodger P. McEver, University of Oklahoma) is directed against GMP-140 (15). GMP-140, also referred to as platelet activation-dependent granule-external membrane (PADGEM) protein (16) , CD62 (17) , and P-selectin (18) , is a component of the a granule membrane of resting platelets that is only expressed on the platelet plasma membrane after platelet secretion (11) . 6D1 (provided by Dr. Barry S. Coller, SUNY, Stony Brook) is directed against the von Willebrand factor receptor on the glycocalicin portion of the a-chain of platelet membrane glycoprotein (GP) lb (19, 20) . AK3 (provided by Dr. Michael C. Berndt, University of Sydney, Australia) is directed against the macroglycopeptide portion of the a chain of platelet membrane GPIb (21) . FMC25 and AK1 (both provided by Dr. Berndt) are directed against platelet membrane GPK (22,23) and the platelet membrane GPIb-DT complex (24), respectively. AK1 only binds to the intact GPIb-K complex, not to uncomplexed GPIb or GPK (24) . Y2/51 (DAKO, Carpinteria, CA) is directed against platelet membrane GPIIIa (25).
Mow Cytometric Analysis of Platelets in Peripheral Whole Blood
The method has been previously described (26) . Blood was drawn by venipuncture from healthy adult volunteers who had not ingested aspirin within the previous 10 days. The first 2 ml of blood were discarded and then blood was drawn directly into a sodium citrate Vacutainer (Becton Dickinson, Rutherford, NJ). Prior to activation, the blood, purified human a-thrombin (provided by Dr. John W. Fenton JJ, New York Department of Health, Albany), the peptide In experiments designed to study the reversibility of hypothermia-induced changes, the method was as above, except that the diluted whole blood (500 piL) was initially incubated at 37°C for 5 minutes and an aliquot was activated with thrombin, then the same blood was cooled to 22°C over 15 minutes and an aliquot activated, and finally the same blood was rewarmed to 37°C over 5 minutes and an aliquot activated. In these experiments, the thrombin was diluted into multiple aliquots on ice and then individual aliquots were equilibrated to the activation temperature.
Platelets in the fixed diluted whole blood samples were labeled with fluorescently conjugated murine monoclonal antibodies as previously described (26) . The samples were then analyzed in an EPICS Profile flow cytometer (Coulter Cytometry, Hialeah, FL) for activationdependent changes in the platelet binding of phycoerythrin-streptavidin/biotin-conjugated antibodies S12 (GMP-140-specific) and 6D1 (GPIb-specific), as previously described (26) .
Fluorescein isothiocyanate (FITC)-conjugated antibody Y2/51 (GPIIIa-specific) was used as the 7 platelet-specific marker (26) . The experimental conditions (diluted whole blood, no stirring, GPRP together with a-thrombin) allowed us to study single platelets in whole blood without inducing the formation of platelet aggregates (26) .
Flow Cytometric Analysis of Platelets and Platelet Aggregates in Whole Blood Emerging from a Bleeding Time Wound
The method of analysis of platelets has been previously described (26) . Simplate II device (General Diagnostics, Durham, NC) as previously described (27) . The blood emerging from the bleeding time wound was collected with a micropipet at 2 minute intervals until the bleeding stopped. After each pipetting, any residual blood at the bleeding time wound site was removed with filter paper. Immediately after collection at each time point, the pipetted blood (1 pL per antibody tested) was added to a microfuge tube containing sodium citrate, fixed for 30 minutes at 22°C with an equal volume of 2% formaldehyde, and diluted 1:10 by volume in modified Tyrode's buffer. As described above, the fixed diluted whole blood samples were 8 then labeled with a FITC-conjugated GPIIIa-specific monoclonal antibody (Y2/51) and either a biotinylated GMP-140-specific monoclonal antibody (S12) or a biotinylated GPIb-IX complexspecific monoclonal antibody (6D1, AK3, FMC25, or AK1), and the individual platelets analyzed in an EPICS Profile flow cytometer for activation-dependent changes. To analyze the number of platelet aggregates in the blood emerging from the bleeding time wound, the fixed diluted whole blood was labeled with both FITC-conjugated monoclonal antibody Y2/51 (GPIIIaspecific) and phycoerythrin-streptavidin/biotin-conjugated monoclonal antibody 6D1 (GPIbspecific), and the samples analyzed by flow cytometry as described in the Results section.
Platelet Aggregometry
Platelets were washed as previously described (28) and resuspended at 250,000/pcL in modified Tyrode's buffer, pH 7.4. The platelets were initially incubated at 37°C for 10 minutes, then the same platelets were cooled to 22°C over 30 minutes, and finally the same platelets were rewarmed to 37°C over 15 minutes. Prior to the activation step, the agonists were diluted into multiple aliquots on ice and individual aliquots were equilibrated to the activation temperature. At each incubation temperature, an aliquot of platelets was removed and incubated with either purified human a-thrombin (final concentration 0.06 -1 U/ml) or U46619 
Radioimmunoassay of Supernatant Thromboxane B 2 In Vitro
In the platelet aggregometry experiments described above, generation of thromboxane B2 was stopped after 5 minutes by the addition of 1 mg/mL ibuprofen (Upjohn, Kalamazoo, MI).
The samples were immediately placed on ice and centrifuged (1,650 g, 10 minutes, 4°C). The supematants were stored at -80°C until assayed for thromboxane B 2 with an RIA kit (New England Nuclear, Boston, MA), as previously described (8) .
Radioimmunoassay of Shed Blood Thromboxane B 2
After the skin temperature of the forearm of a normal volunteer was equilibrated to either 22°C, 28°C, or 32°C, a standardized bleeding time wound was performed, as described above.
Shed blood in 600 /*L aliquots was collected continuously from the beginning to the end of the bleeding time. Each aliquot was assayed for thromboxane Bj with an RIA kit (New England Nuclear), as previously described (8) . The rate of thromboxane Bj generation (pg/0.1 mL/second) was calculated from the total thromboxane Bj generation from all aliquots divided by the bleeding time in seconds.
Data Analysis
Results are expressed as mean ±_ standard error of the mean (S.E.M.) unless otherwise stated. Statistical analysis was performed by Student's t-test for paired or independent samples, 10 as appropriate, of by one way analysis of variance (ANOVA). Differences were considered statistically significant if p values were less than 0.05.
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RESULTS
Effect of Temperature on Activation-induced Changes in Platelet Surface GMP-140 and GPIb
In Vitro
We first examined the effect of hypothermia on thrombin-induced changes in platelet surface expression of GMP-140 and GPIb in vitro (Fig 1) . To avoid the possibility of artefactual platelet activation in vitro, a whole blood flow cytometric method was used (26) . This method did not result in any artefactual platelet activation, as demonstrated by the complete lack of binding of the GMP-140-specific monoclonal antibody S12 in the absence of added exogenous thrombin (Fig 1, panel A , 0 time point). As previously described (26) , at 37°C thrombin resulted in upregulation of the platelet surface expression of GMP-140 (reflecting a granule secretion) (Fig 1, panel A) and, after a delay of approximately 20 seconds, downregulation of the platelet surface expression of GPIb (the von Willebrand factor receptor) (Fig 1, panel B) .
As the temperature was reduced from 37°C to 22°C, the thrombin-induced upregulation of the platelet surface expression of GMP-140 (Fig 1, panel A) and the thrombin-induced downregulation of the platelet surface expression of GPIb (Fig 1, panel B) proceeded more slowly.
However, the final extent of the upregulation of GMP-140 and the downregulation of GPIb was the same irrespective of temperature (Fig 1, panels A and B) .
We then examined the effect of the stable thromboxane A 2 analogue U46619 on platelet surface expression of GMP-140 and GPIb. At 37°C, U46619 resulted in upregulation of the platelet surface expression of GMP-140 to almost the same extent as thrombin (Fig 2, panel A) .
At 37°C, U46619 resulted in downregulation of the platelet surface expression of GPIb, although not to the same extent as thrombin (Fig 2, panel B) . Analogous to the situation with thrombin (Fig 1) , as the temperature was reduced from 37°C to 22°C, the U46619-induced upregulation of the platelet surface expression of GMP-140 (Fig 2, panel A) and the U46619-induced downregulation of the platelet surface expression of GPIb (Fig 2, panel B) proceeded more slowly. Even after 10 minutes incubation of the blood with U46619 at 22°C, the extent of upregulation of GMP-140 and of downregulation of GPIb did not achieve that at 32° and 37°C (Fig 2, panels A and B) .
To compare directly thrombin-and U46619-induced platelet activation at the earliest (and presumably the most physiologically important) time points, data from Figs 1 and 2 were replotted as shown in Figs 3 and 4 . At all temperatures tested (37°C, 32°C, and 22°C), the kinetics of the upregulation jof GMP-140 and the downregulation of GPIb were more rapid with thrombin than with U46619 ( Figs 3 and 4) . Within the first V-h minutes at 22°C, platelets were only minimally activated in response to U46619, whereas they did respond to thrombin, albeit at a slower rate than normal (Fig 3, panel C and Fig 4, panel C) .
Reversibility of Hypothermia-induced Inhibition of Platelet Activation
To address the question as to whether the hypothermia-induced inhibition of platelet activation was reversible, 4 independent assays were utilized:
1) Upregulation of Platelet Surface GMP-140
Diluted whole blood was incubated at 37°C, cooled to 22°C, and then the same whole blood sample was rewarmed to 37°C (Fig 5) . As determined by the whole blood flow cytometric assay, the hypothermia-induced slowing of the kinetics of thrombin-induced completely reversed by rewarming of the blood to 37°C (Fig 5, open circles: panel C) .
2) Downregulation of the Platelet Surface GPIb-IX complex
In the same experiment as in 1) above, the hypothermia-induced slowing of the kinetics of thrombin-induced downregulation of GPIb (Fig 5, closed circles: compare panel A to panel B) was completely reversed by rewarming of the blood to 37°C (Fig 5, closed circles: panel C), as determined by the whole blood flow cytometric assay.
3) Platelet Aggregation
An important functional indication of platelet activation is platelet aggregate formation (14) . Washed platelets were incubated at 37°C, cooled to 22°C, and then . the same platelets were rewarmed to 37°C. Both thrombin-and U46619-induced platelet aggregation was inhibited at 22°C, as determined by shape change, lag phase, slope, and maximal amplitude (Fig 6, compare was an almost complete absence of shape change (Fig 6, panels B and E) . The hypothermiainduced inhibition of platelet aggregation was completely reversed by rewarming of the blood to 37°C, as determined by shape change, lag phase, slope, and maximal amplitude ( (Fig 7: panels A and B) . 
4) Thromboxane B 2 Generation
Generation of thromboxane A 2 is another important marker of platelet activation (13) . In the same experiment as in 3) above, generation of thromboxane B2 (the stable metabolite of thromboxane A^ was assayed in the supernatants 5 minutes after thrombin-induced platelet activation (Fig 7: panels C and D) . As shown for thrombin 0.4 U/mL (Fig 7: panel C) and thrombin 0.16 U/mL (Fig 7: panel D) , thromboxane Rj generation was inhibited at 22°C, but rewarming to 37°C resulted in complete reversal of this inhibition. Similar results were obtained with thrombin 1 U/mL (data not shown).
Effect of Temperature on Platelet Activation In Vivo
To address the question as to whether hypothermia-induced inhibition of platelet activation can occur in vivo, the skin temperature of the forearms of normal volunteers was equilibrated to temperatures between 22°C and 37°C. The shed blood emerging from a standardized bleeding time wound was then analyzed by 5 independent assays of platelet activation:
1) The Bleeding Time
The bleeding time was markedly prolonged by hypothermia (Fig 8) .
Reduction of the skin temperature from 37°C to 22°C resulted in prolongation of the bleeding time from 5.0 + 0.4 to 23.3 + 3.4 minutes (mean + S.E.M., n = 6) (Fig 8) .
2) Upregulation of Platelet Surface GMP-140
Shed blood was analyzed for the normal time-dependent upregulation of platelet surface GMP-140 (26, 29) (Fig 9, panel A) . The time-dependent upregulation of GMP- 140 was abolished by hypothermia (22°C) (Fig 9: panel A) . Again, as indicated by the end points of the solid lines, the bleeding time was prolonged by hypothermia (Fig 9: panels A, B, andC).
3) Downregulation of the Platelet Surface GPIb-IX Complex
Shed blood was analyzed for the normal time-dependent downregulation of the platelet surface GPIb-IX complex (26) (Fig 9, panels B and C) . The time-dependent downregulation of the GPIb-IX complex was almost abolished by hypothermia (22°C), as determined by a GPIb-specific monoclonal antibody (6D1) (Fig 9, panel B) and a GPIb-IX complex-specific monoclonal antibody (AK1) (Fig 9, panel C) . Parallel results were obtained with a monoclonal antibody (AK3) directed against a different epitope on GPIb and a monoclonal antibody (FMC25) directed against GPIX (data not shown).
4) Platelet Aggregate Formation
To analyze the number of platelet aggregates in the blood emerging from the bleeding time wound, the fixed diluted whole blood was labeled and analyzed by flow cytometry as described in Fig 10. Reduction of the forearm skin temperature of normal volunteers resulted in a reduction in both the rate of formation and the maximal number of platelet aggregates emerging from a standardized bleeding time wound (Fig 11) .
5) Thromboxane B 2 Generation
Reduction of the forearm skin temperature of normal volunteers resulted in a reduction of both the rate of generation and the maximal concentration of thromboxane Bj in the blood emerging from a standardized bleeding time wound (Fig 12) . The rate of 16 thromboxane Bj generation (pg/0.1 mL/second) was 2.1 ± 0.7 at 32°C, 0.75 ± 0.2 at 28°C, and 0.09 ± 0.03 at 22°C (mean ± S.E.M., n = 6) (p < 0.05 by ANOVA).
The Effects of Temperature Were Not Confined to a Subpopulation of Platelets
Because each platelet is analyzed individually, the flow cytometric method of analyzing platelet surface glycoproteins is able to detect distinct subpopulations of platelets (30, 31) .
However, in all the experiments described above, the effects of hypothermia were evident on all the platelets, rather than confined to a distinct subpopulation of platelets (data not shown).
Effect of Gender on Temperature-dependent Changes in Platelet Activation
The temperature-dependent changes in platelet activation in vitro and in vivo were not significantly different between male and female volunteers (data not shown).
DISCUSSION
Although a hypothermia-induced hemorrhagic diathesis is known to occur in a number of clinical settings, including hypothermic cardiopulmonary bypass surgery, other major surgery, multiple trauma, exposure, and neonatal cold injury (1-7) , the pathophysiological basis of this hemorrhagic diathesis is not well understood. The hemorrhagic diathesis associated with hypothermic cardiopulmonary bypass surgery is considered to be primarily a platelet function defect (1, 2, 32) . We have recently demonstrated that hypothermia correlates with both prolongation of the bleeding time and postoperative blood loss in patients undergoing cardiopulmonary bypass surgery (3, 33) . However, this clinical setting is complex because even during normothermic cardiopulmonary bypass surgery there is a platelet function defect (2). We (8) and others (2) have demonstrated that hypothermia results in prolongation of the bleeding time in normal baboons. We also recently reported that hypothermia prolongs the bleeding time in normal human volunteers (9) . However, the specificity of the relationship between the bleeding time and platelet function has been challenged (10) .
In the present study, we established that hypothermia inhibits human platelet activation in whole blood in vivo, as determined in normal volunteers by five independent assays of shed blood emerging from a standardized bleeding time wound: 1) upregulation of platelet surface GMP-140 (reflecting a granule secretion), 2) downregulation of the platelet surface GPIb-IX complex (the von Willebrand factor receptor), 3) platelet aggregate formation, 4) thromboxane B 2 generation, and 5) the bleeding time.
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In a previous study in baboons (8) , we reported that the pathophysiological basis for hypothermia-induced platelet dysfunction was, at least in part, inhibition of the action of thromboxane synthetase, resulting in diminished generation of thromboxane A 2 . In the present study in humans, we have confirmed and expanded upon these observations. Thus, hypothermia resulted in lack of generation of thromboxane Rj (the stable metabolite of thromboxane Aj) in humans both in vitro and in vivo. In addition, we now demonstrate that hypothermia inhibits human platelet activation in whole blood in vitro, as determined by or-thrombin-and U46619-induced: a) upregulation of platelet surface GMP-140, b) downregulation of the platelet surface GPIb-IX complex, and c) platelet aggregation and shape change. Thus, in addition to their lack of generation of thromboxane A 2 , hypothermic platelets are less reactive to thromboxane A 2 (as determined by the stable analogue U46619), as well as to thrombin.
In this study, we also demonstrated that rewarming hypothermic blood completely reverses the activation defect, as determined by four independent methods: upregulation of platelet surface GMP-140, downregulation of the platelet surface GPIb-IX complex, platelet aggregation, and thromboxane 1*2 generation. The reversibility of the hypothermia-induced inhibition of platelet activation suggests that rewarming a hypothermic bleeding patient can reduce the need for transfusions of platelets and other blood components. Rewarming of the patient should be considered prior to transfusion given the risks (34) and expense of blood transfusion. Furthermore, once a hypothermia-induced hemorrhagic diathesis develops, transfusion of platelets or plasma is relatively ineffective (5) . The present data suggest that rewarming the patient will result in better function of transfused platelets. Our data also suggest 19 that every effort should be made to maintain normothermia in patients predisposed to hypothermia, such as during major surgery, multiple trauma, and the neonatal period.
The whole blood flow cytometric assay utilized in this study has many advantages over other assays of platelet activation, such as plasma assays of ß-thromboglobulin and platelet factor 4 (35), and should be applicable to many other clinical settings. The assay enabled us to study: 1) human a-thrombin (the preeminent platelet activator in vivo (36) (37) (38) ) in the physiological milieu of whole blood, through the use of GPRP, an inhibitor of fibrin polymerization (26); 2) platelet activation in vivo at the site of a standardized bleeding time wound, because only about 1 fiL of blood is required for the assay (26,29); 3) platelet aggregate formation in vivo (this study); and, 4) activation-induced upregulation of the platelet surface expression of GMP-140 (11) and downregulation of the platelet surface expression of the GPIb-IX complex (12) on individual platelets (26) . In addition, artefactual in vitro platelet activation as a result of experimental manipulation, a major problem in assays such as ß-thromboglobulin and platelet factor 4 (35), was avoided (26, 39) .
In summary, by a combination of immunological, biochemical, and functional assays, we have demonstrated that hypothermia inhibits human platelet activation in whole blood both in vitro and in vivo. Rewarming hypothermic blood completely reverses the activation defect.
These results suggest that rewarming a hypothermic bleeding patient can reduce the need for the less safe and more expensive alternative of transfusion of platelets and other blood components. These data are from the same experiments shown in Fig 1, panel B and Fig 2, The experiment was performed as in Fig 1, except that the blood was initially incubated at 37°C for 5 minutes, then the same blood was cooled to 22°C over 15 minutes, and finally the same blood was rewarmed to 37°C over 5 minutes. At each incubation temperature, an aliquot of whole blood was removed and activated at the 0 time point with thrombin 5 U/ml in the presence of GPRP 2.5 mM (both of which had been equilibrated to the temperature of the blood). Maximum GMP-140 was defmed as the binding of S12 after incubation with thrombin for 15 minutes at the first 37°C incubation. Maximum GPIb was defined as the binding of 6D1 in the absence of thrombin. Data are mean +. S.E.M., n = 3 separate experiments. 
